Skip to main content
Signal8

ORASURE TECHNOLOGIES INC (OSUR)

OraSure Technologies, Inc. and its affiliates are a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools, serving markets across the United States, Europe, and other international regions. The company operates through two primary divisions: Diagnostics and Molecular Solutions. Its diverse Diagnostics portfolio features a range of crucial offerings, such as the InteliSwab rapid tests for COVID-19 (including professional and prescription versions). It also provides several OraQuick rapid tests, encompassing solutions for HIV (Rapid, In-Home, and Self-Test versions), Hepatitis C (HCV rapid antibody), and Ebola (rapid antigen). Further diagnostic tools include the OraSure oral fluid collection device, utilized for HIV-1 antibody screening and confirmation; the Intercept drug testing systems; various immunoassay tests and reagents; and the Q.E.D. saliva alcohol test. Within its Molecular Solutions segment, OraSure offers an array of genomic products, notably under the Oragene and ORAcollect brand names, alongside specialized microbiome collection solutions and comprehensive GenoFIND genomics laboratory services. The company also supplies collection devices like ORAcollect, RNA, OMNIgene, and RAL, specifically designed for COVID-19 molecular testing. Another key offering is the Colli-Pee device, engineered for the precise volumetric collection of first-void urine. Furthermore, OraSure produces and distributes advanced kits for the collection, stabilization, transportation, and storage of genetic material samples, critical for molecular testing in diverse fields such as academic research, commercial applications (including ancestry, disease risk management, lifestyle analysis), and animal testing. Complementing these, it also provides various other diagnostic tools, including immunoassays and in vitro diagnostic tests. OraSure's sophisticated products and services are distributed to a wide array of clients, including clinical laboratories, hospitals, clinics, various community and public health organizations, wholesale distributors, governmental bodies, medical practices, and a broad spectrum of commercial and industrial entities. Established in 2000, OraSure Technologies, Inc. maintains its corporate headquarters in Bethlehem, Pennsylvania.

Sector: Surgical & Medical Instruments & Apparatus

Industry: Medical - Instruments & Supplies

OraSure Technologies, Inc. logo

OraSure Technologies, Inc.

NASDAQ:OSURHealthcare
+8.68%$4.13
AH Close$4.13+0.00%vs close
Mkt Cap$284.84M
Float65.32M
O/S68.97M
Inst Own79.0%
Dilution
Historical Data
DateOpenHighLowCloseVolume
Key Metrics
Market Cap$284.84M
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership79.04%

based on 68.97M shares outstanding

SectorHealthcare
IndustryMedical - Instruments & Supplies
ExchangeNASDAQ
CountryUSUS
IPO Date-
Shares Outstanding68.97M
Float65.32M
Company Overview

OraSure Technologies, Inc. and its affiliates are a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools, serving markets across the United States, Europe, and other international regions.

The company operates through two primary divisions: Diagnostics and Molecular Solutions.

Its diverse Diagnostics portfolio features a range of crucial offerings, such as the InteliSwab rapid tests for COVID-19 (including professional and prescription versions).

It also provides several OraQuick rapid tests, encompassing solutions for HIV (Rapid, In-Home, and Self-Test versions), Hepatitis C (HCV rapid antibody), and Ebola (rapid antigen). Further diagnostic tools include the OraSure oral fluid collection device, utilized for HIV-1 antibody screening and confirmation; the Intercept drug testing systems; various immunoassay tests and reagents; and the Q.E.D. saliva alcohol test. Within its Molecular Solutions segment, OraSure offers an array of genomic products, notably under the Oragene and ORAcollect brand names, alongside specialized microbiome collection solutions and comprehensive GenoFIND genomics laboratory services.

The company also supplies collection devices like ORAcollect, RNA, OMNIgene, and RAL, specifically designed for COVID-19 molecular testing. Another key offering is the Colli-Pee device, engineered for the precise volumetric collection of first-void urine. Furthermore, OraSure produces and distributes advanced kits for the collection, stabilization, transportation, and storage of genetic material samples, critical for molecular testing in diverse fields such as academic research, commercial applications (including ancestry, disease risk management, lifestyle analysis), and animal testing. Complementing these, it also provides various other diagnostic tools, including immunoassays and in vitro diagnostic tests. OraSure's sophisticated products and services are distributed to a wide array of clients, including clinical laboratories, hospitals, clinics, various community and public health organizations, wholesale distributors, governmental bodies, medical practices, and a broad spectrum of commercial and industrial entities. Established in 2000, OraSure Technologies, Inc. maintains its corporate headquarters in Bethlehem, Pennsylvania.

Leadership

Agnieszka Gallagher

Carrie Eglinton Manner

President, Chief Executive Officer & Director

Jack Jerrett

Kathleen G. Weber

Employees

501

Country

US

Sector

Healthcare

Website

orasure.com

Analyst Coverage
Analyst Coverage
ConsensusHold
Price Target
No price targets available
Ratings Distribution
BUY
4
HOLD
9
SELL
0
TOTAL13
Insider Trading
InsiderTypeShares
Boyd Steven Kyle profile photoBoyd Steven KyleGrant/Award4.8K
Kenny John P. profile photoKenny John P.Automatic Sell5.1K
Marmora Lelio profile photoMarmora LelioGrant/Award46.1K
Kenny John P. profile photoKenny John P.Grant/Award46.1K
McMahon Robert W. profile photoMcMahon Robert W.Grant/Award46.1K
Bertrand John D. profile photoBertrand John D.Grant/Award46.1K
Shareholders
79.0%
Institutional
(149)
6.6%
Insiderⓘ
(12)
7.0%
5%+ Owners
(3)
7.3%
Unattributed (incl. retail)ⓘ
Institutional79.0%
Insider6.6%
5%+ Beneficial7.0%
Unattributed (incl. retail)7.3%
Sources: 13F, Form 4, 13D/13GO/S: 69.0M · as of 31 Jul 2026 · SEC cover page
Insiders & Institutional Holders
52-Week Range
$2.08$4.58
$4.13(82nd percentile)
Volume
Average Daily Volume550.11K
1.16M today vs 550.11K avg(+111%)

30d Avg

550.11K

60d Avg

548.45K

90d Avg

515.70K

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...